Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase

• Published in: Stroke (1970) Vol. 54; no. 10; pp. 2491 - 2499
• Main Authors: Checkouri, Thomas, Gerschenfeld, Gaspard, Seners, Pierre, Yger, Marion, Ben Hassen, Wagih, Chausson, Nicolas, Olindo, Stéphane, Caroff, Jildaz, Marnat, Gaultier, Clarençon, Frédéric, Baron, Jean-Claude, Turc, Guillaume, Alamowitch, Sonia
• Format: Journal Article
• Language: English
• Published: United States 01.10.2023
• Subjects: Brain Ischemia - chemically induced; Brain Ischemia - diagnostic imaging; Brain Ischemia - drug therapy; Fibrinolytic Agents - therapeutic use; Humans; Ischemic Stroke - drug therapy; Retrospective Studies; Stroke - chemically induced; Stroke - diagnostic imaging; Stroke - drug therapy; Tenecteplase - therapeutic use; Thrombectomy - methods; Thrombosis - drug therapy; Tissue Plasminogen Activator - therapeutic use; Treatment Outcome; thrombectomy; thrombolytic therapy; thrombus; alteplase; reperfusion; ischemic stroke; tenecteplase
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/STROKEAHA.123.042691

Intravenous thrombolysis (IVT) with alteplase or tenecteplase before mechanical thrombectomy is the recommended treatment for large-vessel occlusion acute ischemic stroke. There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before mechanical thrombectomy, and little data on their potential differences stratified by ER predictors such as IVT to ER evaluation (IVT-to-ER ) time, occlusion site and thrombus length. We retrospectively compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation large-vessel occlusion acute ischemic stroke patients from the PREDICT-RECANAL (alteplase) and Tenecteplase Treatment in Ischemic Stroke (tenecteplase) French multicenter registries. ER was defined as a modified Thrombolysis in Cerebral Infarction score 2b-3 on the first angiographic run, or noninvasive vascular imaging in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (leading to exact balance in patient history, stroke characteristics, and initial management between groups) and confirmed with adjusted logistic regression (sensitivity analysis). A stratified analysis based on pre-established ER predictors (IVT-to-ER time, occlusion site, and thrombus length) was conducted. Overall, 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95% CI, 0.83-1.44]; =0.52). A differential effect of tenecteplase versus alteplase on the probability of ER according to thrombus length was observed ( =0.003), with tenecteplase being associated with higher odds of ER in thrombi >10 mm (odds ratio, 2.43 [95% CI, 1.02-5.81]; =0.04). There was no differential effect of tenecteplase versus alteplase on the likelihood of ER according to the IVT-to-ER time ( =0.40) or occlusion site ( =0.80). Both thrombolytics achieved ER in one-fifth of patients with large-vessel occlusion acute ischemic stroke without significant interaction with IVT-to-ER time and occlusion site. Compared with alteplase, tenecteplase was associated with a 2-fold higher likelihood of ER in larger thrombi.